Imagine a silent invader within the body, cunningly crafting escape routes to spread its destruction far beyond its origin. Breast cancer, one of the most prevalent cancers globally, operates with such stealth, manipulating the lymphatic system to fuel its deadly journey. This roundup dives deep
Diving into the intricate world of cancer biology, we’re thrilled to speak with Ivan Kairatov, a renowned biopharma expert with a profound background in research and development. With a sharp focus on technological innovation in the industry, Ivan has been at the forefront of uncovering how
Imagine a simple stroll down the hallway revealing the future of a patient’s recovery from major hip surgery—sounds almost too straightforward to be true, doesn’t it? Yet, a pioneering study from Kyushu University in Japan has uncovered that the speed at which someone walks before undergoing total
Rising failure rates for single-mechanism therapies in heterogeneous solid tumors have pushed oncology beyond single-target tinkering and into platform-centric thinking that prizes modularity, combinability, and consistent manufacturability across programs. In this shift, antibody-drug conjugates
Imagine a world where a diagnosis of gastric cancer no longer carries the weight of a dire prognosis, where innovative treatments offer a real chance at long-term survival even for those in the early stages of this aggressive disease. This vision is inching closer to reality with the recent
Imagine a hidden ecosystem within the human body, teeming with trillions of microorganisms that quietly shape health, digestion, and even mood. This delicate gut microbiome, a cornerstone of well-being, faces an invisible yet pervasive danger: chemical pollutants. From pesticides on produce to
The drumbeat behind next-generation biologics has been unmistakable, yet the loudest voices in today’s pipelines keep returning to a sobering reality: delivery is not polish at the finish line, it is the race itself, where fragile molecules, strict dosing windows, and hard-to-reach tissues force
For thousands living with spinal muscular atrophy who aged out of early approvals, the FDA’s greenlight of an intrathecal gene therapy redrew the treatment map and challenged long‑held limits. The authorization of Itvisma, an intrathecal formulation of onasemnogene abeparvovec for patients two
After first-line therapy fails in advanced biliary cancer, the next decision can stretch between hope for extra months and fear of heavy toxicity, a fraught balance that now places FOLFIRINOX squarely under the spotlight. Clinics see this crossroads every week: a patient who just progressed on
The scale of diabetic eye screening would swamp any manual system left to grow unchecked, with more than four million people eligible in England and tens of millions of images flowing through a pipeline that still leans on multiple human graders per case to keep patients safe and services moving.
